Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have received an average recommendation of “Moderate Buy” from the fourteen ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, eight have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $93.60.
Several analysts have recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $102.00 target price on shares of Viking Therapeutics in a research note on Monday, March 23rd. Wolfe Research began coverage on Viking Therapeutics in a research note on Thursday, March 26th. They set a “peer perform” rating for the company. BTIG Research restated a “buy” rating and set a $125.00 price objective on shares of Viking Therapeutics in a report on Friday, May 1st. Truist Financial assumed coverage on Viking Therapeutics in a research note on Wednesday, May 27th. They set a “buy” rating and a $83.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Viking Therapeutics in a research report on Monday, April 20th.
Get Our Latest Analysis on Viking Therapeutics
Institutional Investors Weigh In On Viking Therapeutics
Viking Therapeutics Stock Up 2.0%
VKTX opened at $37.08 on Friday. The firm’s 50 day moving average is $33.29 and its 200-day moving average is $32.89. Viking Therapeutics has a 52-week low of $22.96 and a 52-week high of $43.15. The firm has a market capitalization of $4.31 billion, a P/E ratio of -8.96 and a beta of 0.66.
Viking Therapeutics (NASDAQ:VKTX – Get Free Report) last announced its earnings results on Thursday, April 30th. The biotechnology company reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.36). During the same quarter last year, the firm posted ($0.41) EPS. Equities analysts expect that Viking Therapeutics will post -4.7 earnings per share for the current fiscal year.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.
The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.
Read More
- Five stocks we like better than Viking Therapeutics
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
